Feedback
Settings

Settings

Goto Application

30,368 results
Offices all Languages Stemming false Single Family Member true Include NPL false
RSS feed can only be generated if you have a WIPO account

Save query

A private query is only visible to you when you are logged-in and can not be used in RSS feeds

Query Tree

Refine Options

Offices
All
Specify the language of your search keywords
Stemming reduces inflected words to their stem or root form.
For example the words fishing, fished,fish, and fisher are reduced to the root word,fish,
so a search for fisher returns all the different variations
Returns only one member of a family of patents
Include Non-Patent literature in results

Full Query

IC:A61K39/12

Side-by-side view shortcuts

General
Go to Search input
CTRL + SHIFT +
Go to Results (selected record)
CTRL + SHIFT +
Go to Detail (selected tab)
CTRL + SHIFT +
Go to Next page
CTRL +
Go to Previous page
CTRL +
Results (First, do 'Go to Results')
Go to Next record / image
/
Go to Previous record / image
/
Scroll Up
Page Up
Scroll Down
Page Down
Scroll to Top
CTRL + Home
Scroll to Bottom
CTRL + End
Detail (First, do 'Go to Detail')
Go to Next tab
Go to Previous tab

Analysis

1 / 3,037
1.20240245767APPLICATION OF ARTIFICIALLY SYNTHESIZED CPG SINGLE-STRANDED DEOXYOLIGONUCLEOTIDE IN VACCINES
US - 25.07.2024
Int.Class A61K 39/39
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
39characterised by the immunostimulating additives, e.g. chemical adjuvants
 Appl.No 18557748 Applicant PARR BIOTECHNOLOGY (HEBEI) CO., LTD Inventor Ligong WANG

The disclosure provides a composition comprising CpG ODN and one or more other adjuvants that work together with the immunomodulatory CpG ODN, such as an aluminum adjuvant, wherein the CpG ODN comprises or consists of a nucleotide sequence selected from SEQ ID NOs: 1-4, wherein at least one nucleotide in the nucleotide sequence is a chemically modified nucleotide having a structure of formula (I):

embedded image

wherein, Y is S or O, R is H or a positively charged counterion, B is independently an unmodified or modified nucleobase, and R1 is H, F, CI, OH, OMe, Me, O-ethyloxymethyl.

Use of the composition, a pharmaceutical composition comprising the composition, a preparation method thereof, and use of the pharmaceutical composition are also disclosed.

2.WO/2024/155907EPITOPE-SCAFFOLD IMMUNOGENS FOR PANCORONAVIRUS VACCINES
WO - 25.07.2024
Int.Class A61K 39/215
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
12Viral antigens
215Coronaviridae, e.g. avian infectious bronchitis virus
 Appl.No PCT/US2024/012189 Applicant DUKE UNIVERSITY Inventor AZOITEI, Mihai
Disclosed are immunogens for stimulating an immune response to coronaviruses. The immunogens can be non-receptor binding domain (RED) epitopes. The immunogens can be grafted into a scaffold polypeptide to produce an epitope scaffold. Antibodies induced by the immunogens are disclosed.
3.WO/2024/152533RECOMBINANT CHIMERIC ANTIGEN FOR POXVIRUS, SUBUNIT VACCINE COMPRISING SAME AND USE THEREOF
WO - 25.07.2024
Int.Class C07K 14/065
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
005from viruses
01DNA viruses
065Poxviridae, e.g. avipoxvirus
 Appl.No PCT/CN2023/107061 Applicant PEKING UNIVERSITY Inventor XI, Jianzhong Jeff
Provided are a recombinant chimeric antigen for a poxvirus, in particular for a Mpoxvirus, a subunit vaccine comprising the recombinant chimeric antigen, and a use thereof. The recombinant chimeric antigen of the present application comprises two immunogens arranged in a specific manner: a Mpoxvirus A35 protein or an antigenic fragment thereof or derivative peptides of same, and a Mpoxvirus M1 protein or an antigenic fragment thereof or derivative peptides of same, and can excite an immune response to two infectious virus particles of intracellular mature virus (IMV) particles and extracellular enveloped virus (EEV) particles.
4.WO/2024/152998USE OF CPG ADJUVANT IN PREPARATION OF NOVEL CORONAVIRUS VACCINE
WO - 25.07.2024
Int.Class A61K 39/39
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
39characterised by the immunostimulating additives, e.g. chemical adjuvants
 Appl.No PCT/CN2024/071939 Applicant PARR BIOTECHNOLOGY (HEBEI) CO., LTD. Inventor WANG, Ligong
Use of a CpG adjuvant in the preparation of a novel coronavirus vaccine. Provided is a composite adjuvant, comprising the CpG adjuvant and an A1 adjuvant. The nucleotide sequence of the CpG adjuvant is SEQ ID NOs: 1-5. Provided is a novel coronavirus vaccine, consisting of a novel coronavirus antigen, and the CpG adjuvant and the A1 adjuvant in a first aspect. Provided is a composition (vaccine) for stimulating or eliciting an immune response against SARS-CoV-2. The immune response includes, but is not limited to, an immune response that generates a neutralizing antibody against SARS-CoV-2 and is biased towards Thl. CpGODN is a fully phosphorothioated oligodeoxynucleotide containing non-methylated CG dinucleotide (CpG) linked by phosphorus (p), and has an immunostimulatory effect.
5.WO/2024/153118IMPLEMENTATION OF DIRECTED EVOLUTION AND DARWINIAN ADAPTATION IN MAMMALIAN CELLS BY MEANS OF REPLICABLE RNA
WO - 25.07.2024
Int.Class C12N 15/40
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
11DNA or RNA fragments; Modified forms thereof
31Genes encoding microbial proteins, e.g. enterotoxins
33Genes encoding viral proteins
40Proteins from RNA viruses, e.g. flaviviruses
 Appl.No PCT/CN2024/072737 Applicant PEKING UNIVERSITY Inventor MA, Liang
An orthogonal alphavirus RNA replication system, i.e., an RNA replicase-assisted continuous in vivo evolution (REPLACE) system, and an REPLACE method. An RNA-based evolution element makes REPLACE of mammalian cells possible. According to the method, more than one billion replicable RNA copies can be continuously diversified and selected, and RNA replication and powerful inducible RNA mutation by means of replicase restriction are achieved. According to the method, new functions of fluorescent proteins, transcription factors and miniature Cas proteins (dCasMINI) are evolved or existing functions are improved. Cells equipped with REPLACE can adapt to challenges from the exterior or interior of the cells by continuously evolving the replicable RNA carrying cancer-related key genes (i.e., MEK1 and KRAS). An RNA-based evolution platform will provide a new high-performance tool kit for mammalian synthetic biology, and assist in adaptive engineering modification of mammalian cells and tissues.
6.WO/2024/153793NUCLEIC ACID MOLECULES
WO - 25.07.2024
Int.Class A61K 39/12
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
12Viral antigens
 Appl.No PCT/EP2024/051250 Applicant ASTRAZENECA AB Inventor LOO, Yueh-Ming
The present disclosure relates to a nucleic acid molecule comprising 5'-UTR and/or 3'-UTR sequences that yield high translation levels. Aspects of the disclosure further relate to nucleic acid molecules suitable for use as a vaccine in the treatment and prevention of infectious diseases, including those caused by a coronavirus, compositions comprising said nucleic acid molecules and methods of treating or preventing infectious diseases.
7.WO/2024/154048VACCINES AGAINST RESPIRATORY DISEASES
WO - 25.07.2024
Int.Class A61K 39/12
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
12Viral antigens
 Appl.No PCT/IB2024/050404 Applicant PFIZER INC. Inventor BERMAN, Damon Andrew Hollands
The present disclosure relates to hMPV F, PIV3 F and PIV1 F protein mutants, nucleic acids or vectors encoding a hMPV F, PIV3 F and PIV1 F protein mutant, compositions comprising a hMPV F, PIV3 F and PIV1 F protein mutant or nucleic acid, and uses of the hMPV F, PIV3 F and PIV1 F protein mutants, nucleic acids or vectors, and compositions.
8.20240248080Kaposi sarcoma associated herpesvirus gene function
US - 25.07.2024
Int.Class G01N 33/50
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33Investigating or analysing materials by specific methods not covered by groups G01N1/-G01N31/131
48Biological material, e.g. blood, urine; Haemocytometers
50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
 Appl.No 18629922 Applicant The Regents of the University of California Inventor Fenyong Liu

Kaposi's sarcoma-associated herpesvirus (KSHV) is an opportunistic pathogen causing Kaposi's sarcoma. It is capable of establishing latent infection, which can be reactivated to engage lytic infection for progeny production. KSHV contains a ˜165 kilobase DNA genome predicted to encode at least 90 open reading frames (ORFs). In this report, we generated 91 KSHV mutants, each characterized by the disruption of a single viral ORF. The growth of these mutants in cultured cells was examined to systematically investigate the necessity of each ORF for viral latency, reactivation, and lytic replication. Salient aspects are (a) 44 ORFs are essential for viral lytic replication in cultured cells and 47 are nonessential; (b) KSHV reactivation can be positively or negatively regulated by specific viral ORFs; and (c) ORFs identified to regulate viral reactivation encode functions modulating both innate and adaptive immune responses. The intersection of viral immunomodulatory genes controlling reactivation suggests that KSHV engages in a concerted effort to communicate and respond to the host immune system for reactivation and replication using a viral sensory network. Our results imply a novel mechanism in which reactivation of KSHV is actively controlled by the virus in response to its surrounding environment, leading to the opportunistic nature of viral diseases that are strongly correlated to the host's immune status and conditions.

9.WO/2024/153953mRNA COMPOSITIONS
WO - 25.07.2024
Int.Class A61K 39/12
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
12Viral antigens
 Appl.No PCT/GB2024/050155 Applicant SISAF LTD Inventor SAFFIE-SIEBERT, Roghieh Suzanne
Disclosed is an mRNA vector composition, comprising: mRNA; one or more particles comprising hydrolysable silicon; and one or more lipids, characterised in that the mRNA is mRNA which is not chemically modified. Also disclosed are related products, methods and uses.
10.20240247033SARS-COV-2 RBD CONSTRUCTS
US - 25.07.2024
Int.Class C07K 14/005
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
005from viruses
 Appl.No 18002611 Applicant The Scripps Research Institute Inventor William SCHIEF

The present invention relates to glycan-masked and membrane-tethered SARS-CoV-2 RBD vaccine constructs and methods for making and administering the same. The present invention also encompasses a general vaccine platform for coronaviruses.

# -